1). (2) Generalized progression (GP) was defined as an increase in tumor size (PD in RECIST criteria), with an enhancing pattern in two or more tumor masses (Figure selleckchem Pacritinib (Figure2).2). (3) New solid lesion (NS), with or without a cystic component, was defined as the appearance of one or more new lesions that had an enhancing lesion with or without a cystic component (Figure (Figure3).3). (4) Generalized cystic change (GC) was defined as the appearance of cystic change in two or more tumor masses (Figure (Figure4).4). (5) New cystic lesion (NC) was defined as the appearance of one or more new lesions that had relatively low density, without any enhancing component (Figure (Figure55). Figure 1 FP pattern. Contrast-enhanced CT of the abdomen obtained from a 39-year-old woman with metastatic GIST in the right lobe of liver.
A: Before imatinib therapy, the lesion showed ill-defined thickened rim enhancement (arrow); B: After 2 mo therapy, a nearly … Figure 2 GP pattern. Contrast-enhanced CT of abdomen obtained from a 55-year-old man with metastatic GIST in the mesentery. A: Before imatinib treatment, there were mesenteric masses (arrows); B: After 2 mo therapy, there was interval progression in both mesenteric … Figure 3 NS pattern. Contrast-enhanced CT scan of abdomen obtained in a 39-year-old woman with metastatic GIST in the liver. A: Before imatinib treatment, a large subcapsular cystic lesion in the right hepatic lobe and a small amount of free fluid were noted; … Figure 4 GC pattern. Contrast-enhanced CT scan of the abdomen obtained in a 64-year-old man with metastatic GIST in both lobes of the liver (arrows).
A: Before imatinib treatment, there were a few rather ill-defined, small homogeneous enhancing lesions in the … Figure 5 NC pattern. Contrast-enhanced CT scan of abdomen in 50-year-old woman with metastatic GIST in the liver. A: Before imatinib treatment, no liver metastases were visible at this level; B: Contrast-enhanced CT after 2 mo treatment with imatinib. At least … Statistical analysis Statistic analysis was performed with STATA software (StataCorp LP, College Station, TX, USA). Patient age, tumor location, overall response, and pattern of tumor changes were analyzed. Survival was calculated from the day of imatinib treatment until death or the final day of the patient��s visit to the outpatient clinic. Kaplan�CMeier analysis with a log rank test was used to compare patterns of CT changes and survival distribution. P < 0.05 was considered to indicate a significant difference between groups. RESULTS Patient characteristics There were 17 patients included in this study (13 men and four women) with a median age Entinostat of 52 years (range 36-69 years).
No related posts.